54B7F258-FE9A-4EFE-87FB-465D587B1170
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 4.533508541392904
- age_years
- 68
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | E97A62A3-E4D3-435C-9165-C0075358578E | — | — | 0.950 |
| 2 | AB5294B5-4A59-493A-9016-C2778735745F | — | — | 0.944 |
| 3 | 812834CD-DA8F-4C0C-A49E-31D4A882D0E0 | — | — | 0.939 |
| 4 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.939 |
| 5 | C5C8713B-05C1-4C5C-8685-2A546B99BA50 | — | — | 0.939 |
| 6 | 33800B09-6DCC-4BE8-891C-5F34ADAC65B3 | — | — | 0.938 |
| 7 | BB96C5BA-CA50-40B4-B22A-3FCFE46AB11C | — | — | 0.937 |
| 8 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.935 |
| 9 | 769432C5-4BFD-4689-8F43-467010292448 | — | — | 0.934 |
| 10 | 52F6F0A9-8D2D-49BC-9B49-E20E5E53561C | — | — | 0.933 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.561 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.491 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.489 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.475 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.463 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.458 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.396 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.370 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.349 | Inavolisib | — uncovered |
| APOPTOSIS | 0.348 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.347 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.344 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.332 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.321 | Inavolisib | — uncovered |
| PEROXISOME | 0.301 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.299 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.283 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.270 | Remibrutinib | — uncovered |